Click here to close now.

SYS-CON MEDIA Authors: Liz McMillan, AppDynamics Blog, tru welu, Blue Box Blog, Kevin Jackson

News Feed Item

Inflammatory Bowel Diseases: World Drug Market 2013-2023

NEW YORK, Sept. 2, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Inflammatory Bowel Diseases: World Drug Market 2013-2023

Report Details

Medicines for bowel inflammation - you explore R&D and potential sales

What's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential revenues.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging technologies. Try our new report.

Analysis of what shapes the IBD drugs industry and determines its potential

Discover what the future holds for agents treating inflammatory bowel disorders: Crohn's disease and ulcerative colitis. Read on, then, to explore that drug industry and see what its future market could be worth.

Forecasts to 2023 and other data show you commercial potentials

Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 74 tables, 34 charts, and three interviews.

You know how hard it can be to find data. All that searching. Now, though, you can stay ahead in knowledge for IBD medicine, benefiting your research, analyses, and decisions.

Avoid falling behind. Also save time. Finding information you need just got easier. There, in our study, you hear what's happening and see where the money lies.

The following sections, then, show what you get in our new investigation.

Prospects for the world market and submarkets for IBD medications

Our report shows revenue to 2023 for the overall world IBD drug market. It also shows you individual forecasts for five submarkets:

• Aminosalicylates

• Antibiotics

• Corticosteroids

• Biologic therapies (biological drugs)

• Immunomodulators.

How will those colonic medicines perform? Which classes of lower-gut treatment will generate most money? There you assess prospects for revenue growth.

Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential for those intestinal medicines. See how you can benefit.

You also find revenue predictions for leading products.

Forecasts for IBD drugs - what outlooks for sales?

How will top drugs perform to 2023 at world level? Our report forecasts individual revenues of 14 products, including these:• Humira• Remicade• Asacol• Pentasa• Lialda• Tysabri• Xifaxan• Cimzia• Entocort.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you examine competition. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our investigation also divides its overall IBD world forecast into geographical regions.

National markets for treating those gastrointestinal disorders

Developments worldwide expand the inflammatory bowel treatment market. Hear about the best revenue prospects.

In developed and developing countries, many opportunities for producers and sellers of those drugs will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:• US• Japan• Germany, France, UK, Italy, and Spain (EU5)• China, India, Brazil, and Russia (BRIC).

There you discover progress and outlooks. Product launches from 2013 to 2023 will change the commercial landscape.

Research and development - assess innovation, trends, and possibilities

What about R&D - pipelines for new drugs? You assess trends there, including for these agents:

• Interleukin (IL) inhibitors

• Cell-adhesion molecule (CAM) inhibitors

• TNF alpha inhibitors

• Stem cell therapies

• Immunomodulators

• Chemokine receptors

• Antioxidants and barrier function therapies.

That R&D explores many molecular pathways and targets. It holds promise. You hear about innovations there - developments and their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our new study explains, discussing issues to help your work.

Issues affecting manufacturing and selling of IBD treatments

Our report also shows you issues and events affecting that industry and market from 2013, including these:

• Nature of ulcerative colitis and Crohn's disease

• Aetiology and epidemiology of IBD

• Monoclonal antibodies (mAbs) as medications

• Delivery systems for agents

• Vaccines and alternative therapy

• Genotyping and improvements to treatments.

There you explore political, economic, social, and technological questions, assessing outlooks for the business. You also analyse that industry's strengths, weaknesses, opportunities, and threats. Discover now what the future holds.

Companies leading that industry and 2017 market value

From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our study predicts the world market for IBD drugs will reach $9.6bn in 2017, and expand further to 2023.

Our work shows you what technologies, products, and organisations hold greatest potential. In particular, it investigates these companies:

• AbbVie

• Janssen Biotech

Warner Chilcott

• Shire Pharmaceuticals.

From 2013 there exist prospects for new drugs and overall sales growth. Our report shows you the possibilities, helping you stay ahead.

Eight ways Inflammatory Bowel Diseases: World Drug Market 2013-2023 helps you

To sum up, then, our research and analysis give you the following knowledge:• Revenue to 2023 of the world market for IBD medicines - discover that industry's overall sales potential• Revenues to 2023 for 5 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and sales• Revenues to 2023 for 14 products - find sales outlooks for top brands, seeing how they can compete and succeed• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth• Assessments of top companies - hear about participants' activities, capabilities, results, and outlooks• Review of R&D - explore progress in research and development, finding technological and medical possibilities• Interviews with authorities on the field - discover debates and opinions to help you stay ahead• Competition and opportunities - investigate what shapes that market's future, including ways to develop business and succeed.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity for treating those gastrointestinal diseases. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.

Treatment of IBD - assess its potential now, seeing what you can gain

Our new study shows you data, trends, opportunities, and sales predictions for drugs treating inflammatory bowel disorders. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 Inflammatory Bowel Disease Market Overview

1.2 Aims, Scope and Format of the Report

1.3 Chapter Outlines

1.4 Research and Analysis Methods

2. Introduction to the Inflammatory Bowel Disease Market

2.1 What is Inflammatory Bowel Disease (IBD)?

2.2 Are There Different Types of IBD?

2.3 Signs, Symptoms and Associated Conditions

2.4 What Causes Inflammatory Bowel Disease?

2.5 How Common is Inflammatory Bowel Disease?

3. Drug Treatments for Inflammatory Bowel Diseases

3.1 Can IBD be Cured?

3.2 What Are the Medications Used to Treat IBD?

3.2.1 Aminosalicylates - The Most Common Therapy

3.2.2 Corticosteroids - Limited in the Long-Run?

3.2.3 Immunomodulators - Slow to Act?

3.2.4 Monoclonal Antibodies - The Future?

3.2.5 Antibiotics - Do they Really Help?

3.3 Treatment Protocol

4. The World Inflammatory Bowel Disease Market, 2013-2023

4.1 The Inflammatory Bowel Disease Market in 2012: Domination of Biologics and Aminosalicylates

4.2 Forecast 2013-2023: Any Major Changes Expected?

4.3 Aminosalicylates Forecast 2013-2023: The Work-Horse of IBD Therapy

4.4 Antibiotics Forecast 2013-2023: Will They Still Be Relevant in a Decade?

4.5 Biologic Therapies Forecast 2013-2023: Main Driver of Growth

4.6 Corticosteroids Forecast 2013-2023: Continued Insignificance?

4.7 Immunomodulators Forecast 2013-2023

5. Leading National Markets, 2013-2023

5.1 IBD Drugs - Leading National Markets, 2012

5.2 The US IBD Drug Market, Revenues 2013-2023 - Leader of the Pack

5.2.1 Case Study: What is the Relative Contribution of Ulcerative Colitis and Crohn's Disease to Total IBD Spending in the US?

5.3 The Japanese IBD Drug Market, Revenues 2013-2023 - Tomorrow's Leader?

5.4 The EU-5 IBD Drug Markets, Revenues 2013-2023 - Europe's Growth Potential

5.5 IBD Drug Markets in BRIC Countries, Revenues 2013-2023 - Vast Potential for Sales

5.5.1 Brazil: Revenues 2013-2023

5.5.2 Russia: Revenues 2013-2023

5.5.3 India: Revenues 2013-2023

5.5.4 China: Revenues 2013-2023

6. Market Prospects for Leading IBD Drugs, 2013-2023

6.1 Humira (AbbVie) - The Leading Therapy

6.1.1Humira: Forecast and Analysis, 2013-2023

6.2 Remicade (Janssen Biotech) - A Worthy Challenger?

6.2.1Remicade: Forecast and Analysis, 2013-2023

6.3 Asacol (Warner Chilcott) - The Best Mesalazine Formulation?

6.3.1Asacol: Forecast and Analysis, 2013-2023

6.4 Pentasa (Shire USA) - When Will a Generic Substitute Arrive?

6.4.1 Pentasa: Forecast and Analysis, 2013-2023

6.5 Lialda (Shire USA) - What Potential for that Medication?

6.5.1 Lialda: Forecast and Analysis, 2013-2023

6.6 Tysabri (Elan Pharmaceuticals) - Will Side Effects Prove Too Much?

6.6.1 Tysabri: Forecast and Analysis, 2013-20236.7 Xifaxan (Salix Pharmaceuticals)

6.7.1 Xifaxan: Forecast and Analysis, 2013-20236.8 Cimzia (UCB Inc.) - Approved in Only a Handful of Countries

6.8.1 Cimzia: Forecast and Analysis, 2013-2023

6.9 Entocort (AstraZeneca) - Prominent Steroid Treatment

6.9.1 Entocort: Forecast and Analysis, 2013-2023

6.10 Neoral (Novartis) - A Widely Used Immunosuppressant

6.10.1 Neoral: Forecast and Analysis, 2013-2023

6.11 Medrol (Pfizer Inc.) - Another Leading Steroid

6.11.1 Medrol: Forecast and Analysis, 2013-2023

6.12 Canasa/Salofalk (Aptalis Pharmaceuticals) - A Slow Decline

6.12.1 Canasa/Salofalk: Forecast and Analysis, 2013-2023

6.13 Apriso (Salix Pharmaceuticals) - A Serious Challenger to Asacol?

6.13.1 Apriso: Forecast and Analysis, 2013-2023

6.14 Azulfidine (Pfizer Inc.) - What Scope for Revenue Growth?

6.14.1 Azulfidine: Forecast and Analysis, 2013-2023

7. The R&D Pipeline for Inflammatory Bowel Disease, 2013

7.1 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation

7.1.1 Profile: Vidofludimus (4SC)

7.2 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue

7.2.1 Profile: Etrolizumab (Roche)

7.3 TNF-? Inhibitors - A Tried and Tested Target

7.3.1 Profile: Ozoralizumab (Ablynx)

7.4 Stem Cell Therapies - Basis for a Cure?

7.4.1 Profile: Remestemcel-L (Osiris Therapeutics)

7.5 Janus Kinase (JAK) Inhibitors - More Targets to Hit

7.5.1 Profile: Tasocitinib (Pfizer)

7.6 Immunomodulators - Will They Live Up To the Hype?

7.6.1 Profile: ZP1848 (Zealand Pharma)

7.7 Chemokine Receptors - Potential Exists

7.7.1 Profile: Vercirnon (ChemoCentryx/GSK)

7.8 Antioxidants and Barrier Function

7.8.1 Profile: Tetomilast (Otsuka) - The Future of IBD Treatment?

8. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2013-2023

8.1 SWOT and STEP Analysis of the IBD Market

8.2 What Factors Will Drive the IBD Market?

8.2.1 Increasing Disease Incidence

8.2.2 Better Diagnosis

8.2.3 Nature of the Disease

8.2.4 Delivery Systems

8.2.5 Biological Drugs

8.2.6 Socioeconomic Costs of IBD

8.3 What Factors Will Restrain the Market?

8.3.1 Lack of Understanding of Disease Aetiology

8.3.2 Compliance

8.3.3 Limits of Biologics

8.3.4 A Cure or Vaccine

8.3.5 The Possible Development of Alternative Treatments

8.3.6 Surgery - When Other Options Fail

9. Leading Companies in the IBD Market, 2013

9.1 The Largest Companies by Revenue

9.2 AbbVie - The Leader in a Highly Profitable Area

9.3 Janssen Biotech - Tomorrow's Powerhouse?

9.4 Warner Chilcott - A Strong Competitor

9.5 Shire Pharmaceuticals - Still a Major Player in the Future?

10. Research Interviews

10.1 Dr Qamar ul Arfin, Gastroenterologist, Aga Khan University Hospital, Karachi, Pakistan

10.1.1 On Antibiotics in Treating IBD

10.1.2 On the Emergence of Biologic Therapies

10.1.3 On IBD in the Pakistani Context

10.1.4 On Any Preventative Measures that Can Be Taken

10.2 Professor John Hermon-Taylor, King's College London

10.2.1 The Significance of MAP in Crohn's

10.2.2 Rising Incidence of IBD

10.2.3 Defining IBD

10.2.4 Timeframe of MAP Vaccine

10.2.5 Antibiotic Activity of Other Crohn's Treatments

10.2.6 Alternative Treatments

10.2.7 Ethics of Crohn's Drug Development

10.2.8 The Impact of a Vaccine on the Market

10.2.9 On Claims that MAP is Not Implicated in CD

10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney

10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology

10.3.2 IBD and HIV/AIDS

10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments

10.3.4 Potential Cure?

10.3.5 Remicade and MAP10.3.6 Genotyping

10.3.7 Crohn's vs. Colitis

10.3.8 Future Therapies

10.3.9 The Potential and Future of Myoconda

11. Conclusions

11.1 IBD Market to Expand from 2013 to 2023

11.2 Aminosalicylates and Other Non-Biologic Treatments

11.3 Biologic Treatments

11.4 Improvements Needed in IBD Treatments

11.5 Future IBD Treatments: R&D Efforts Look Promising

11.6 The IBD Sector: Looking to the Future with Confidence

List of Tables

Table 2.1 World Incidence Rates for IBD, 2013

Table 2.2 Geographical Variations in the Incidence of IBD, 2013

Table 3.1 Other Drug Types Used to Treat IBD, 2013

Table 4.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012

Table 4.2 Global IBD Drug Market Forecast ($m), 2012-2023

Table 4.3 Global IBD Drug Forecast by Drug Category ($m), 2012-2023

Table 4.4 Global IBD Drug Market Drivers and Restraints, 2012-2023

Table 4.5 Global Aminosalicylates Forecast ($m), 2012-2023

Table 4.6 Global Aminosalicylates Drivers and Restraints, 2012-2023

Table 4.7 Global Antibiotics Forecast ($m), 2012-2023

Table 4.8 Global Antibiotics Drivers and Restraints, 2012-2023

Table 4.9 Global Biologic Therapies Forecast ($m), 2012-2023

Table 4.10 Global Biologic Therapies Drivers and Restraints, 2012-2023

Table 4.11 Global Corticosteroid Forecast ($m), 2012-2023

Table 4.12 Global Corticosteroids Drivers and Restraints, 2012-2023

Table 4.13 Global Immunomodulators Forecast ($m), 2012-2023

Table 4.14 Global Immunomodulators Drivers and Restraints, 2012-2023

Table 5.1 Global IBD Drug Revenues by Geographical Segments ($m), 2012

Table 5.2 Global IBD Drug Market Forecasts by Country ($m), 2012-2023

Table 5.3 US IBD Drug Market Forecast ($m), 2012-2023

Table 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023

Table 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023

Table 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023

Table 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023

Table 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023

Table 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023

Table 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023

Table 6.1 Leading IBD Treatments by Revenue ($m), 2012

Table 6.2 Leading IBD Medicines: Revenue Forecasts ($m), 2012-2023

Table 6.3 World Humira Revenue Forecast ($m), 2012-2023

Table 6.4 Drivers and Restraints for Humira, 2012-2023

Table 6.5 World Remicade Revenue Forecast ($m), 2012-2023

Table 6.6 Drivers and Restraints for Remicade, 2012-2023

Table 6.7 World Asacol Revenue Forecast ($m), 2012-2023

Table 6.8 Drivers and Restraints for Asacol, 2012-2023

Table 6.9 World Pentasa Revenue Forecast ($m), 2012-2023

Table 6.10 Drivers and Restraints for Pentasa, 2012-2023

Table 6.11 World Lialda Revenue Forecast ($m), 2012-2023

Table 6.12 Drivers and Restraints for Lialda, 2012-2023

Table 6.13 World Tysabri Revenue Forecast ($m), 2012-2023

Table 6.14 Drivers and Restraints for Tysabri, 2012-2023

Table 6.15 World Xifaxan Revenue Forecast ($m), 2012-2023

Table 6.16 Drivers and Restraints for Xifaxan, 2012-2023

Table 6.17 World Cimzia Revenue Forecast ($m), 2012-2023

Table 6.18 Drivers and Restraints for Cimzia, 2012-2023

Table 6.19 World Entocort Revenue Forecast ($m), 2012-2023

Table 6.20 Drivers and Restraints for Entocort, 2012-2023

Table 6.21 World Neoral Revenue Forecast ($m), 2012-2023

Table 6.22 Drivers and Restraints for Neoral, 2012-2023

Table 6.23 World Medrol Revenue Forecast ($m), 2012-2023

Table 6.24 Drivers and Restraints for Medrol, 2012-2023

Table 6.25 World Canasa Revenue Forecast ($m), 2012-2023

Table 6.26 Drivers and Restraints for Canasa, 2012-2023

Table 6.27 World Apriso Revenue Forecast ($m), 2012-2023

Table 6.28 Drivers and Restraints for Apriso, 2012-2023

Table 6.29 World Azulfidine Revenue Forecast ($m), 2012-2023

Table 6.30 Drivers and Restraints for Azulfidine, 2012-2023

Table 7.1 Selected IL Inhibitors in Clinical Development, 2013

Table 7.2 Selected CAM Inhibitors in Clinical Development, 2013

Table 7.3 Selected TNF-Alfa Inhibitors in Clinical Development, 2013

Table 7.4 Selected Stem Cell Therapies in Clinical Development, 2013

Table 7.5 Selected Immunomodulators in Clinical Development, 2013

Table 7.6 Selected Chemokine Receptors in Clinical Development, 2013

Table 7.7 Selected Antioxidants and Barrier Function Therapies in Clinical Development, 2013

Table 8.1 SWOT Analysis of the World IBD Drug Market, 2012-2023

Table 8.2 STEP Analysis of the World IBD Drug Market, 2012-2023

Table 9.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2012

Table 9.2 AbbVie Revenues ($m) and Market Share (%), 2012

Table 9.3 Janssen Biotech Revenues ($m) and Market Share (%), 2012

Table 9.4 Warner Chilcott Revenues ($m) and Market Share (%), 2012

Table 9.5 Shire's Revenues ($m) and Market Share (%), 2012

Table 11.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Product Category, 2013, 2017, 2023

Table 11.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Geographical Regions, 2013, 2017, 2023

Table 11.3 Summary of IBD Market Drivers and Restraints, 2013-2023

List of Figures

Figure 3.1 Treatment Protocol for IBD, 2013

Figure 4.1 World IBD Drugs Market Shares by Product Type (%), 2012

Figure 4.2 Global IBD Drug Market Forecast ($m), 2012-2023

Figure 4.3 World IBD Drugs Market Shares by Product Type (%), 2023

Figure 4.4 Global Aminosalicylates Forecast ($m), 2012-2023

Figure 4.5 Global Antibiotics Forecast ($m), 2012-2023

Figure 4.6 Global Biologic Therapies Forecast ($m), 2012-2023

Figure 4.7 Global Corticosteroid Forecast ($m), 2012-2023

Figure 4.8 Global Immunomodulators Forecast ($m), 2012-2023

Figure 5.1 Global IBD Drug Market by Geographical Segments (%), 2012

Figure 5.2 Global IBD Drug Market by Geographical Segments (%), 2023

Figure 5.3 US IBD Drug Market Forecast ($m), 2012-2023

Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023

Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023

Figure 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023

Figure 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023

Figure 6.1 World Humira Revenue Forecast ($m), 2012-2023

Figure 6.2 World Remicade Revenue Forecast ($m), 2012-2023

Figure 6.3 World Asacol Revenue Forecast ($m), 2012-2023

Figure 6.4 World Pentasa Revenue Forecast ($m), 2012-2023

Figure 6.5 World Lialda Revenue Forecast ($m), 2012-2023

Figure 6.6 World Tysabri Revenue Forecast ($m), 2012-2023

Figure 6.7 World Xifaxan Revenue Forecast ($m), 2012-2023

Figure 6.8 World Cimzia Revenue Forecast ($m), 2012-2023

Figure 6.9 World Entocort Revenue Forecast ($m), 2012-2023

Figure 6.10 World Neoral Revenue Forecast ($m), 2012-2023

Figure 6.11 World Medrol Revenue Forecast ($m), 2012-2023

Figure 6.12 World Canasa Revenue Forecast ($m), 2012-2023

Figure 6.13 World Apriso Revenue Forecast ($m), 2012-2023

Figure 6.14 World Azulfidine Revenue Forecast ($m), 2012-2023

Figure 9.1 Top 4 Companies for IBD Drugs: Market Shares (%), 2012

Companies Listed


Abbott Laboratories



Active Biotech

Aga Khan University Hospital

Ajinomoto Group

Amalyte Pharmaceuticals

Aptalis Pharmaceuticals




Atlantic Pharmaceuticals

Biogen Idec

Bristol-Myers Squibb

Cambridge Antibody Technology

Catabasis Pharmaceuticals

Celgene Cellular Therapies

Celltech Pharmaceuticals

Centocor Ortho Biotech

Centre for Digestive Diseases, Sydney

Centres for Disease Control and Prevention


China Medical

Cosmo Pharmaceuticals

Crohn's and Colitis Foundation of America

Crohn's and Colitis Foundation of Canada

Elan Corporation

European Federation of Crohn's and Ulcerative Colitis Associations

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)



GlaxoSmithKline (GSK)

Harbor BioSciences

Hutchison MediPharma

InDex Pharmaceuticals

Isis Pharmaceuticals

Janssen Biotech

Johnson & Johnson

King's College London

Kyorin Pharmaceutical Co.

Lipid Therapeutics


Merck & Co.

Mylan Pharmaceuticals




Osiris Therapeutics

Otsuka Pharmaceutical Group

Palau Pharma

PDL BioPharma


Probiotic Therapy Research Centre, Sydney, Australia

Procter & Gamble Pharmaceuticals

Prometheus Laboratories


Salix Pharmaceuticals


Shire Pharmaceuticals Group

Sigmoid Pharma


Teva Pharmaceutical Industries



Warner Chilcott

World Gastroenterology Organisation (WGO)

Zealand Pharma

To order this report:Drug_and_Medication Industry: Inflammatory Bowel Diseases: World Drug Market 2013-2023


Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001


SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!
You use an agile process; your goal is to make your organization more agile. But what about your data infrastructure? The truth is, today's databases are anything but agile - they are effectively static repositories that are cumbersome to work with, difficult to change, and cannot keep pace with application demands. Performance suffers as a result, and it takes far longer than it should to deliver new features and capabilities needed to make your organization competitive. As your application an...
Want to enable self-service provisioning of application environments in minutes that mirror production? Can you automatically provide rich data with code-level detail back to the developers when issues occur in production? In his session at DevOps Summit, David Tesar, Microsoft Technical Evangelist on Microsoft Azure and DevOps, will discuss how to accomplish this and more utilizing technologies such as Microsoft Azure, Visual Studio online, and Application Insights in this demo-heavy session.
As cloud gives an opportunity to businesses to buy services externally – how is cloud impacting your customers? In his General Session at 15th Cloud Expo, Fabio Gori, Director of Worldwide Cloud Marketing at Cisco, provided answers to big questions: Do you see hybrid cloud as where the world is going? What benefits does it bring? And how does Cisco connect all of these clouds? He also discussed Intercloud and Cisco’s investment on it.
The Internet of Things is not new. Historically, smart businesses have used its basic concept of leveraging data to drive better decision making and have capitalized on those insights to realize additional revenue opportunities. So, what has changed to make the Internet of Things one of the hottest topics in tech? In his session at @ThingsExpo, Chris Gray, Director, Embedded and Internet of Things, discussed the underlying factors that are driving the economics of intelligent systems. Discover ...
Health care systems across the globe are under enormous strain, as facilities reach capacity and costs continue to rise. M2M and the Internet of Things have the potential to transform the industry through connected health solutions that can make care more efficient while reducing costs. In fact, Vodafone's annual M2M Barometer Report forecasts M2M applications rising to 57 percent in health care and life sciences by 2016. Lively is one of Vodafone's health care partners, whose solutions enable o...
In her General Session at 15th Cloud Expo, Anne Plese, Senior Consultant, Cloud Product Marketing, at Verizon Enterprise, focused on finding the right mix of renting vs. buying Oracle capacity to scale to meet business demands, and offer validated Oracle database TCO models for Oracle development and testing environments. Anne Plese is a marketing and technology enthusiast/realist with over 19+ years in high tech. At Verizon Enterprise, she focuses on driving growth for the Verizon Cloud platfo...
Andi Mann has been serving as Conference Chair of the DevOps Summit since its inception. He is one of the world's recognized leaders in DevOps, and continues to be one of its most articulate advocates. Here are some recent thoughts of his in an interview we conducted in the run-up to the DevOps Summit to be held June 9-11 at the Javits Center in New York City. When did you first start thinking about DevOps and its potential impact on enterprise IT? Andi: I first started thinking about DevOps b...
The most often asked question post-DevOps introduction is: “How do I get started?” There’s plenty of information on why DevOps is valid and important, but many managers still struggle with simple basics for how to initiate a DevOps program in their business. They struggle with issues related to current organizational inertia, the lack of experience on Continuous Integration/Delivery, understanding where DevOps will affect revenue and budget, etc. In their session at DevOps Summit, JP Morgentha...
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
The speed of product development has increased massively in the past 10 years. At the same time our formal secure development and SDL methodologies have fallen behind. This forces product developers to choose between rapid release times and security. In his session at DevOps Summit, Michael Murray, Director of Cyber Security Consulting and Assessment at GE Healthcare, examined the problems and presented some solutions for moving security into the DevOps lifecycle to ensure that we get fast AND ...
SYS-CON Events announced today that MetraTech, now part of Ericsson, has been named “Silver Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. Ericsson is the driving force behind the Networked Society- a world leader in communications infrastructure, software and services. Some 40% of the world’s mobile traffic runs through networks Ericsson has supplied, serving more than 2.5 billion subscribers.
The OpenStack cloud operating system includes Trove, a database abstraction layer. Rather than applications connecting directly to a specific type of database, they connect to Trove, which in turn connects to one or more specific databases. One target database is Postgres Plus Cloud Database, which includes its own RESTful API. Trove was originally developed around MySQL, whose interfaces are significantly less complicated than those of the Postgres cloud database. In his session at 16th Cloud...
How does one bridge the gap between traditional enterprise storage infrastructures and the private, hybrid, and public cloud? In his session at 15th Cloud Expo, Dan Pollack, Chief Architect of Storage Operations at AOL Inc., examed the workload differences and required changes to reuse existing knowledge and components when building and using a cloud infrastructure. He also looked into the operational considerations, tool requirements, and behavioral changes required for private cloud storage s...